JP2023512786A5 - - Google Patents

Info

Publication number
JP2023512786A5
JP2023512786A5 JP2022547882A JP2022547882A JP2023512786A5 JP 2023512786 A5 JP2023512786 A5 JP 2023512786A5 JP 2022547882 A JP2022547882 A JP 2022547882A JP 2022547882 A JP2022547882 A JP 2022547882A JP 2023512786 A5 JP2023512786 A5 JP 2023512786A5
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkenyl
substituents
independently selected
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547882A
Other languages
English (en)
Japanese (ja)
Other versions
JP7681030B2 (ja
JP2023512786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016948 external-priority patent/WO2021159015A1/en
Publication of JP2023512786A publication Critical patent/JP2023512786A/ja
Publication of JP2023512786A5 publication Critical patent/JP2023512786A5/ja
Priority to JP2025035491A priority Critical patent/JP2025087835A/ja
Application granted granted Critical
Publication of JP7681030B2 publication Critical patent/JP7681030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547882A 2020-02-07 2021-02-05 Namptモジュレーター Active JP7681030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025035491A JP2025087835A (ja) 2020-02-07 2025-03-06 Namptモジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062971838P 2020-02-07 2020-02-07
US62/971,838 2020-02-07
PCT/US2021/016948 WO2021159015A1 (en) 2020-02-07 2021-02-05 Nampt modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025035491A Division JP2025087835A (ja) 2020-02-07 2025-03-06 Namptモジュレーター

Publications (3)

Publication Number Publication Date
JP2023512786A JP2023512786A (ja) 2023-03-29
JP2023512786A5 true JP2023512786A5 (enExample) 2024-02-13
JP7681030B2 JP7681030B2 (ja) 2025-05-21

Family

ID=74858766

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547882A Active JP7681030B2 (ja) 2020-02-07 2021-02-05 Namptモジュレーター
JP2025035491A Pending JP2025087835A (ja) 2020-02-07 2025-03-06 Namptモジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025035491A Pending JP2025087835A (ja) 2020-02-07 2025-03-06 Namptモジュレーター

Country Status (16)

Country Link
US (1) US20230133132A1 (enExample)
EP (1) EP4100393A1 (enExample)
JP (2) JP7681030B2 (enExample)
KR (1) KR20220152537A (enExample)
CN (1) CN115515934B (enExample)
AR (1) AR121282A1 (enExample)
AU (1) AU2021217402A1 (enExample)
BR (1) BR112022014728A2 (enExample)
CA (1) CA3168838A1 (enExample)
CL (1) CL2022002106A1 (enExample)
CO (1) CO2022012773A2 (enExample)
IL (2) IL321884A (enExample)
MX (1) MX2022009771A (enExample)
PH (1) PH12022552021A1 (enExample)
TW (1) TWI908763B (enExample)
WO (1) WO2021159015A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
JP2025542258A (ja) 2022-12-22 2025-12-25 サイトキネティックス, インコーポレイテッド Namptモジュレーター
WO2025243724A1 (ja) * 2024-05-20 2025-11-27 国立研究開発法人国立精神・神経医療研究センター 神経保護剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
PT1037880E (pt) 1997-12-11 2004-11-30 Janssen Pharmaceutica Nv Anilidas mimeticas do acido retinoico
DE10208986A1 (de) 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US20130317027A1 (en) 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
BR112012021806A2 (pt) 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
CN106986856A (zh) 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドPlexxikon Inc. キナーゼをモジュレートするための化合物および方法、ならびにその指標
US11452717B2 (en) * 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
CN106916101B (zh) 2017-02-15 2020-05-01 聚缘(上海)生物科技有限公司 Nampt/hdac双靶点抑制剂及其制备方法

Similar Documents

Publication Publication Date Title
CN111315737B (zh) 经砜吡啶烷基酰胺取代的杂芳基化合物
JP2019510787A5 (enExample)
JP2024050527A5 (enExample)
Cynamon et al. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity
JP2023508772A (ja) Jak阻害剤化合物及びその使用
HUE027171T2 (en) 1-Phenyl-2-pyridinylalkyl alcohol derivatives as phosphodiesterase inhibitors
JP2012522759A5 (enExample)
JP2004531490A5 (enExample)
JP2014037426A5 (enExample)
JP2010502706A5 (enExample)
JP2022534704A5 (enExample)
JP2022534709A5 (enExample)
JP2025508323A5 (enExample)
JP5875863B2 (ja) マレイン酸オルブピタントの無水結晶形
JP2024536862A5 (enExample)
WO1994012499A1 (fr) Derive de 1,8-naphthyridin-2-one et utilisation de ce derive
JP2023549051A5 (enExample)
JP2023502745A5 (enExample)
JP2020518676A5 (enExample)
IL295296A (en) Nampet Modulators
JPS6051466B2 (ja) ピリジン誘導体およびその製造法
JPH05194491A (ja) イミダゾリルメチル−ピリジン
JPS62294682A (ja) エルゴリンエステル、その製造方法およびそれを含有する医薬組成物
JP2001510188A (ja) ピラジン誘導体、それらの製造及びそれらを含有する薬剤
JP2022521474A5 (enExample)